Genetic Analysis AS (“Genetic Analysis” or the “Company”) published on May 28th the Company’s Q1-report for 2026.
The following are some key points that we have chosen to highlight in connection with the report:
In summary, Genetic Analysis delivered a strong Q1-26 with sales growth of 60% driven by continued momentum in high-margin recurring reagent kit sales. The quarter was further characterised by improved European traction and continued US expansion, supporting the view that Genetic Analysis is well positioned as the rapidly growing microbiome market shifts towards a more diagnostic approach. Combined with the first commercial order from China, marking an important strategic milestone, and a high pace of product development including the recent AInsight launch and the upcoming IBD Precision Dx, the Company has expanded its product portfolio meaningfully over the past year, supporting accelerated growth going forward. Profitability is expected to improve in line with continued sales growth, even though gross margin headwinds from tariffs and currency are expected to persist in the short term.
Read Analyst Group’s comment on the report here
About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
This is a press release from Analyst Group regarding the publication of a comment on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.